

# Markus Pfirrmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6677374/publications.pdf>

Version: 2024-02-01

23  
papers

2,515  
citations

623734

14  
h-index

794594

19  
g-index

24  
all docs

24  
docs citations

24  
times ranked

1730  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death. <i>Hematologic Malignancies</i> , 2021, , 119-143.	0.2	0
2	CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphomaâ€”Diagnostic, Therapeutic, and Prognostic Relevance. <i>Frontiers in Neurology</i> , 2021, 12, 654543.	2.4	13
3	The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2138-2149.	7.2	55
4	Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. <i>American Journal of Hematology</i> , 2019, 94, 1236-1243.	4.1	17
5	The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. <i>Leukemia</i> , 2019, 33, 1173-1183.	7.2	83
6	Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study. <i>Molecular Metabolism</i> , 2018, 9, 168-175.	6.5	12
7	No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 843-850.	2.5	34
8	Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death. <i>Cancer</i> , 2017, 123, 2467-2471.	4.1	18
9	Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7049-7049.	1.6	0
10	Prognostic Scores for Patients with Chronic Myeloid Leukemia Under Particular Consideration of Disease-Specific Death. <i>Hematologic Malignancies</i> , 2016, , 111-128.	0.2	0
11	Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death. <i>Annals of Hematology</i> , 2015, 94, 209-218.	1.8	22
12	Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. <i>Haematologica</i> , 2014, 99, 1441-1447.	3.5	97
13	Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. <i>Journal of Clinical Oncology</i> , 2014, 32, 415-423.	1.6	271
14	Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1367-1381.	2.5	5
15	Clinical Trials in Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 109-115.	2.3	3
16	Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. <i>Blood</i> , 2011, 118, 686-692.	1.4	413
17	Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon- $\gamma$ in Newly Diagnosed Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 1634-1642.	1.6	307
18	Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. <i>Blood</i> , 2010, 115, 1880-1885.	1.4	198

#	ARTICLE	IF	CITATIONS
19	Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood, 2007, 109, 4686-4692.	1.4	141
20	The European Leukemia Net CML Registry - Objectives, Achievements and First Results.. Blood, 2006, 108, 4781-4781.	1.4	0
21	Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with $\alpha$ -interferon: comments. British Journal of Haematology, 2001, 114, 241-241.	2.5	7
22	Interferon- $\alpha$ Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure. Blood, 1999, 94, 3668-3677.	1.4	91
23	A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group. Journal of the National Cancer Institute, 1998, 90, 850-859.	6.3	728